Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2021-04-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于《深圳华大基因股份有限公司2020年度内部控制评价报告》的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an opinion from CITIC Securities on the "2020 Internal Control Evaluation Report" of Shenzhen BGI Genomics Co., Ltd. It discusses the scope, methodology, and conclusions of the internal control evaluation for the year 2020. The document is a verification or review opinion on the internal control report rather than the report itself. It references regulatory frameworks and internal control standards but does not contain full financial statements or comprehensive financial data. The document length is 2091 characters, which is relatively short and consistent with an opinion or certification rather than a full report. Therefore, it fits best under Audit Report / Information (AR), which includes audit reports, applied accounting principles, and internal control evaluations, excluding full annual reports. FY 2020
2021-04-25 Chinese
关于2021年度为子公司提供担保额度预计的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Genomics Co., Ltd. regarding the estimated guarantee amount for subsidiaries in 2021. It includes extensive financial data of subsidiaries, descriptions of guarantee types, approval procedures, and opinions from the board, independent directors, and supervisory board. The document is an official announcement about the company's planned provision of guarantees to its subsidiaries, including the scope, limits, and risk assessments. It is not a full financial report, audit report, or earnings release, but rather a regulatory announcement about financing-related guarantees and approvals. This fits best under Capital/Financing Update (CAP) as it concerns updates on company financing activities (guarantees to subsidiaries). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive update on financing matters.
2021-04-25 Chinese
关于使用暂时闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the use of temporarily idle own funds for cash management. It details the board and supervisory committee approvals, investment purpose, risk analysis, and related opinions. The document is a formal disclosure about financing activities related to cash management and investment of idle funds, not a financial report or earnings release. It does not contain financial statements or results but rather an update on capital usage and risk management. Therefore, it fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters and is a full announcement, not a brief notice or a report publication announcement.
2021-04-25 Chinese
关于增加2021年度日常关联交易预计额度的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the increase in the estimated amount of daily related-party transactions for the year 2021. It details the nature of these transactions, the related parties involved, pricing policies, and approvals from the board, independent directors, and supervisory board. The document includes no financial statements or comprehensive financial data but focuses on corporate governance and compliance with stock exchange rules regarding related-party transactions. It is not a full annual or interim report, audit report, earnings release, or any other financial report. It is a regulatory announcement about related-party transactions and their approval process, fitting best under Regulatory Filings (RNS). The document length (8004 characters) and content confirm it is not a mere report publication announcement but a substantive regulatory disclosure.
2021-04-25 Chinese
2020年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2020 by Shenzhen BGI Genomics Co., Ltd. It discusses the company's internal control systems, evaluation scope, control activities, risk assessments, and conclusions about the effectiveness of internal controls as of December 31, 2020. The content is detailed and comprehensive, covering internal control policies, procedures, and compliance with regulatory requirements. It is not a full annual report or financial statement but a specialized report focused on internal control evaluation. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations. The document length (8652 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2020
2021-04-25 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 28th meeting of the second Supervisory Board of Shenzhen BGI Genomics Co., Ltd. It includes approvals of the 2020 Annual Report, 2021 Q1 Report, 2020 Supervisory Board Work Report, financial budgets, profit distribution plans, audit firm reappointment, internal control reports, and other governance and financial matters. The document is not the reports themselves but a formal announcement of the Supervisory Board's review and approval of these reports and proposals, with many items noted as needing shareholder approval. It also includes voting results and references to where the actual reports are published (e.g., on cninfo.com.cn). The document length is 6971 characters, which is substantial but the content is clearly a meeting resolution announcement rather than the full reports. This fits the category of Regulatory Filings (RNS) as it is a regulatory announcement of supervisory board meeting resolutions and approvals, not the full annual or quarterly reports themselves.
2021-04-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.